Is, used to treat Parkinson's disease, affect the gut microbiota, leading to levodopa degradation before it reaches the brain ...

Motor function improved with a favorable safety profile for patients with Parkinson’s disease who used tavapadon while receiving oral levodopa, according to a study published in JAMA Neurology.This ...

Detailed results from the phase 3 TEMPO trials show tavapadon offers a mechanistically distinct approach for managing motor ...

The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking carbidopa/levodopa drugs. Both AbbVie and Novartis market levodopa-based ...

Please provide your email address to receive an email when new articles are posted on . Once-daily opicapone 50 mg with carbidopa/levodopa helped achieve and maintain plasma concentrations of levodopa ...

For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives ...

Significant reduction also seen in change from baseline in daily OFF times vs placebo. HealthDay News — For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...

A recent study finds that the addition of rasagiline (marketed as Azilect) to the treatment regimen of individuals with Parkinson’s disease significantly enhances clinical outcomes. The study was ...

The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...

The FDA issued a safety communication today warning of a potential increased risk of seizures tied to certain medications used to treat Parkinson's disease. The agency will require manufacturers of ...